Physician profile
Nancy Taft
NPI 1366496028
$1,550.58
in general payments reported to CMS, 2019-2025
14 companies · $88.74 in 2025
The $88.74 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $75.37 · 2022: $87.57 · 2023: $919 · 2024: $186 · 2025: $88.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $600 · Food and Beverage: $565 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $600.00 |
| Food and Beverage | $564.66 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $630.00 | 2023 | |
| Tactile Systems Technology INC | $230.84 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Leica Microsystems INC. | $190.00 | 2023 | |
| Lilly USA, LLC | $87.25 | 2019-2020 | |
| Medtronic, INC. | $86.62 | 2023 | Plasmablade(Tm) |
| Fujifilm New Development USA, INC. | $85.33 | 2019 | |
| Kci USA, INC. | $73.06 | 2022 | |
| Genentech USA, INC. | $40.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $34.55 | 2025 | |
| Amgen INC. | $28.60 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $22.65 | 2024 | Myrisk |
| Baxter Healthcare | $14.51 | 2022 | |
| Merck Sharp & Dohme LLC | $13.18 | 2019 | |
| Puma Biotechnology, INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Taft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.